MWB Consulting Ltd., which advises international clients on development and postmarketing support of pharmaceuticals and medical devices, has joined SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries. The company plans to use SAFE-BioPharma digital signatures to achieve a fully electronic business environment internally and with its clients.
MWB Consulting offers services across the entire product development pathway including clinical development consulting, a full pharmacovigilance provision (through its fully owned affiliate company Medanta Pharmacovigilance), regulatory support, submissions and post-marketing compliance. The firm also provides due diligence activities for product licensing and investment opportunities, and provides interim management.
“Our goal is to eliminate paper from our operations. Using SAFE-BioPharma digital signatures we’ll be able to store and access everything electronically,” said Mr. Bradley Norton, Consultant Partner, MWB Consulting.
SAFE-BioPharma digital signatures remove the time and costs associated with printing, handling and storing paper documents. Documents can be reviewed, approved and signed using electronic workflows. Approvals that took days take minutes. The digital signature can be used to sign every conceivable form, contract or other document used anywhere in the biopharmaceutical or healthcare industries. The SAFE-BioPharma standard also is used extensively for digital identity management and facilitates interoperability across different information systems.
“Membership in SAFE-BioPharma will allow MWB Consulting to interface more efficiently and seamlessly with clients who also are members,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.
MWB Consulting joined SAFE-BioPharma using the association’s new small-entity pricing.
About MWB Consulting Limited
MWB Consulting Limited, based in Northamptonshire, UK, was incorporated in 2000. The firm’s rapid growth is based on in-house expertise and a network of consulting experts in various pharmaceutical disciplines. The team within MWB Consulting has broad therapeutic experience including cardiovascular; dermatology; endocrinology, gastroenterology, immunology/infectious disease, medical devices, musculoskeletal, nephrology/urology, neurology/psychiatry, obstetrics and gynecology, oncology and paediatrics/neonatology.
About SAFE-BioPharma Association
SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.
The Association’s members include:
- Abbott (NYSE: ABT)
- Amarin Corp. (NASDAQ: AMRN)
- Amgen (NASDAQ: AMGN)
- AstraZeneca (NYSE: AZN)
- Bristol-Myers Squibb (NYSE: BMY)
- GlaxoSmithKline (NYSE: GSK)
- Johnson & Johnson (NYSE: JNJ)
- Eli Lilly (NYSE: LLY)
- McDougall Scientific
- Merck (NYSE: MRK)
- MWB Consulting Limited
- National Notary Association
- Novartis (NYSE: NVS)
- Oxford Outcomes
- Pfizer (NYSE: PFE)
- Premier Inc.
- Sanofi-Aventis (NYSE: SNY)
- ScheringPlough-Organon (NYSE: SGP)
- SNAP Diagnostics
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.